Glioblastoma is the most frequent malignant primary brain tumor. In a hierarchical tumor model, glioblastoma stem-like cells (GSC) play a major role in tumor initiation and maintenance as well as in therapy resistance and recurrence. Thus, targeting this cellular subset may be key to effective immunotherapy. Here, we present a mass spectrometry-based analysis of HLA-presented peptidomes of GSC and glioblastoma patient specimens. Based on the analysis of patient samples (n = 9) and GSC (n = 3), we performed comparative HLA peptidome profiling against a dataset of normal human tissues. Using this immunopeptidome-centric approach we could clearly delineate a subset of naturally presented, GSC-associated HLA ligands, which might serve as highly specific targets for T cell-based immunotherapy. In total, we identified 17 antigens represented by 41 different HLA ligands showing natural and exclusive presentation both on GSC and patient samples. Importantly, in vitro immunogenicity and antigen-specific target cell killing assays suggest these peptides to be epitopes of functional CD8+ T cell responses, thus rendering them prime candidates for antigen-specific immunotherapy of glioblastoma.
Introduction
Glioblastoma, the most frequent malignant primary brain tumor, carries a poor prognosis despite advances in surgery, radiation-and chemotherapy [37] . This dilemma calls for innovative approaches, one of the most promising of which Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s0040 1-018-1836-9) contains supplementary material, which is available to authorized users.
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is T cell-based immunotherapy. The impressive clinical efficacy of immune checkpoint inhibitors in a subset of patients with extracranial malignancies demonstrates the potential of T cell-based immunotherapy to induce and maintain longlasting anti-tumor immune responses [4, 10, 29] . Since the clinical benefit of immune checkpoint inhibition is associated with high numbers of tumor-associated somatic mutations and since this mutational burden is rather low in glioblastoma [1] , T cell epitopes from non-mutated sources may represent the most actionable targets in glioblastoma. Such targets may be utilized to boost or direct the specificities of anti-tumoral T cell responses, e.g., by combination therapies of checkpoint blockade and peptide vaccination or in adoptive cellular approaches. In this context, the identification of appropriate targets is crucial. A central challenge in targeting a highly heterogeneous tumor such as glioblastoma is to prevent positive clonal selection of antigen loss variants [19] .
In recent years, there is growing evidence for the presence of glioma-initiating cells exhibiting stem cell properties, which can be designated as glioblastoma stem-like cells (GSC) [9, 27] . In a hierarchical tumor model, GSC are supposed to have important functions in the initiation, maintenance, and therapy resistance of glioblastoma and therefore warrant evaluation as a possible target for immunotherapy.
By mapping the HLA peptidome of glioblastoma and GSC, we identified a new panel of T cell antigens characterized by exclusive detection on malignant specimens, a high frequency of presentation as well as representation on the glioblastoma stem cell compartment. This study is based on the in-depth HLA peptidome analysis of 3 established GSC lines (GS-2, GS-5, GS-9), which have been characterized extensively for stable stemness properties [9, 40] , as well as 9 freshly resected glioblastoma samples. This glioblastoma cohort was analyzed in relation to a comprehensive dataset of HLA ligands presented on various normal human tissues including normal human brain. In contrast to previous studies on the HLA peptidome of glioblastoma [7, 20] our extensive dataset allows for a purely HLA peptidome-centric analysis of the antigenic landscape of bulk patient tumors and the glioblastoma stem cell compartment as represented by GSC. Notably, cluster and network analyses revealed direct evidence for the gliogenesis and stem cell fate determination being reflected in the intersection of patient tumor and GSC immunopeptidomes. Furthermore, in vitro priming assays demonstrated the induction of specific T cell responses for a subset of these novel target candidates, underscoring their potential for T cell immunotherapy.
Materials and methods

Patients and blood samples
Primary tissue of patients with histologically confirmed glioblastoma who underwent surgery at the Department of Neurosurgery at the University Hospital Zurich was immediately snap-frozen in liquid nitrogen during surgery and stored at − 80 °C. Written informed consent was obtained from each glioblastoma patient as well as from patients and healthy donors that contributed to the normal tissue database in accordance with the local ethical requirements and the Declaration of Helsinki. Institutions that contributed samples to the normal tissue database are listed in the Supplementary Methods (Online Resource 1).
Peripheral blood mononuclear cells (PBMC) of healthy donors for functional experiments were isolated by density gradient centrifugation. HLA typing of cell lines and tumor samples was carried out at the Department of Hematology and Oncology, University of Tübingen, Germany. PBMC of HLA-typed healthy donors were provided by the Department of Transfusion Medicine, University of Tübingen, Germany, and by the Swiss Red Cross Blood Transfusion Services Zurich and Chur, Switzerland.
All analyses were performed according to the guidelines of the local ethics committees (KEK-ZH-Nr. 2015-0163).
Cell lines and GSC culture expansion
We used established GSC lines GS-2, GS-5, GS-9, which have been characterized extensively for stable stemness properties [9, 40] . GSC were provided by the Department of Neurosurgery at the University Hospital HamburgEppendorf. Cells were tested for mycoplasma contamination every 3 months using a PCR-based test kit. Cell line authentication and exclusion of cross-contamination was performed showing stable HLA typing (PCR with sequence-specific primers) from original cell lines and cell pellets used for experiments. GSC were thawed around passages 15-20 and before using the cells for experiments they were passaged 6-8 times. GSC were maintained in neurobasal medium with B-27 supplement (20 µl/ml) and glutamax (10 µl/ml) (all Invitrogen, Karlsruhe, Germany), as well as fibroblast growth factor (FGF)-2, epidermal growth factor (EGF) (20 ng/ml each; Peprotech, Rocky Hill, PA, USA) and heparin (32 IE/ml; Ratiopharm, Ulm, Germany). Stem cell factors were supplemented twice a week, the medium was changed once a week. Cells were passaged when spheres reached an estimated diameter of 500 μm or an estimated density of 5 × 10 4 cells/cm 2 . Spheres were dissociated mechanically and enzymatically 1 3 (accutase; PAA, Vienna, Austria). After culture expansion, GSC line cell pellets (1 ml each) were harvested and snapfrozen. Three experimental replicates per GSC line were produced and each experimental replicate was used for the isolation of HLA ligands with subsequent analysis by LC-MS/MS in 5 technical replicates (as described below).
Immunofluorescence
× 10
5 cells were cytospun onto a glass slide, dried for 30 min and fixed in 4% formaldehyde for 10 min. Subsequently, the cells were stained using mouse monoclonal primary antibody to HLA-A, -B, -C (EMR8-5; 1:50; BD Pharmingen, Franklin Lakes, NJ, USA) or the mouse monoclonal primary antibody to HLA class II (ab55152; 1:50; Abcam, Cambridge, UK) followed by permeabilization with 0.5% Triton X100 and incubation with goat anti-rabbit IgG-Alexa Fluor 488-coupled secondary antibody (Invitrogen) (diluted 1:100) and nuclear DNA labeling with DAPI (Invitrogen) for visualization. Images were acquired using a Leica SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany).
Immunohistochemistry
Immunohistochemistry was carried out on cytospins (prepared as described above) or paraformaldehyde-fixed paraffin-embedded glioma sections. Cytospins or sections were stained using the mouse monoclonal primary antibody to HLA-A, -B, -C (1:50) (BD Pharmingen) or the mouse monoclonal primary antibody to HLA class II (1:50) (Abcam) and visualized using anti-mouse secondary antibody with the ImmPACT DAB kit (Vector, Burlingame, CA, USA). Binding specificity was controlled by an isotype control. Images were acquired using a Zeiss Scope.A1 microscope (Carl Zeiss Microscopy, Jena, Germany).
Isolation of HLA ligands
HLA class I molecules were isolated using standard immunoaffinity purification [8, 16] . In brief, snap-frozen GSC pellets or snap-frozen primary glioblastoma tissue samples were lysed in 10 mM CHAPS/PBS (AppliChem, St. Louis, MO, USA/Gibco, Carlsbad, CA, USA) containing 1× protease inhibitor (Complete; Roche, Basel, Switzerland). HLA molecules were single-step purified using the pan-HLA class I-specific mAb W6/32 (produced in-house) covalently linked to CNBr-activated Sepharose (GE Healthcare, Chalfont St Giles, UK). For the immunoprecipitation of HLA class II-peptide complexes, we used equal amounts of the HLA-DR-specific antibody L243 as well as the pan-HLA class IIspecific antibody Tü39 (both produced in-house). HLA-DR1 is known to be expressed at higher levels than the other class II allotypes, therefore the specific L243 mAb at the given stoichiometry was used. Tü39 is utilized complementarily to pull-down the remaining class II complexes. HLA-peptide complexes were eluted by repeated addition of 0.2% TFA (trifluoroacetic acid, Merck, Whitehouse Station, NJ, USA). Eluted HLA ligands were purified by ultrafiltration using centrifugal filter units (Amicon; Millipore, Billerica, MA, USA). HLA ligands were desalted using ZipTip C18 pipette tips (Millipore). Extracted peptides were eluted in 35 μl 80% acetonitrile (Merck)/0.2% TFA, vacuum-centrifuged to complete dryness and resuspended in 25 μl of 1% acetonitrile/0.05% TFA. Samples were stored at − 20 °C until analysis by LC-MS/MS.
Analysis of HLA ligands by LC-MS/MS
Peptide samples were separated by reversed-phase liquid chromatography (nano-UHPLC, UltiMate 3000 RSLCnano; Thermo Fisher, Waltham, MA, USA) and analyzed in online-coupled LTQ Orbitrap XL or Orbitrap Fusion Lumos mass spectrometers (both Thermo Fisher). Samples were analyzed in five (Orbitrap XL) or three (Fusion Lumos) technical replicates. Sample shares of 20% (Orbitrap XL) or 10% (Fusion Lumos) were trapped on a 75 μm × 2 cm trapping column (Acclaim PepMap RSLC; Thermo Fisher) at 4 μl/ min for 5.75 min. Peptide separation was performed at 50 °C and a flow rate of 175 nl/min on a 50 μm × 25 cm separation column (Acclaim PepMap RSLC; Thermo Fisher) applying a gradient ranging from 2.4 to 32.0% of acetonitrile over the course of 90 min. The majority of samples were analyzed on an LTQ Orbitrap XL using a top five CID (collision-induced dissociation) method with survey scans at 60k resolution and fragment ion detection in the ion trap (ITMS2) operated at normal scan speed. Seven normal tissue specimens from the central nervous system (brain04-brain07 and cerebellum04, cerebellum06, cerebellum07) were analyzed on the Orbitrap Fusion Lumos for tumor-exclusivity validation of targets implementing a top-speed CID method with survey scans at 120k resolution and fragment detection in the Orbitrap (OTMS2) at 60 k resolution. On both instruments, the mass range was limited to 400-650 m/z with precursors of charge states 2+ and 3+ eligible for fragmentation. For HLA class II, a mass range of 300-1500 m/z was analyzed with charge states ≥ 2 selected for fragmentation.
Database search and spectral annotation
The software Proteome Discoverer (v.1.3; Thermo Fisher) was used to perform database search using the Mascot search engine (Mascot 2.2.04; Matrix Science, London, UK) for ITMS2 data and Sequest (Thermo Fisher) for OTMS2 data. The human proteome as comprised in the Swiss-Prot database (http://www.unipr ot.org, status September 2013, 20,225 1 3 reviewed sequences contained) was used as reference database. The search combined data of technical replicates and was not restricted by enzymatic specificity. Precursor mass tolerance was set to 5 ppm, and fragment mass tolerance to 0.5 Da for ITMS2 data and 0.02 Da for OTMS2 data, respectively. Oxidation of methionine residues was allowed as a dynamic modification. False discovery rate (FDR) was estimated using the Percolator node [14] and was limited to 5%. ITMS2 peptide IDs were further filtered for Mascot Ion scores ≥ 20. For HLA class I ligands, peptide lengths were limited to 8-12 amino acids (AA), for HLA class II, peptides were limited to 12-25 AA of length. Protein grouping was disabled, allowing for multiple annotations of peptides, e.g., for conserved sequences mapping into multiple proteins. As a final step of quality control, thresholds of ≥ 500 (HLA class I, primary glioblastoma tissue), ≥ 200 (HLA class I, GSC), unique ligand identifications per sample were applied. HLA annotation was performed using the prediction tool SYFPEITHI (http://www.syfpe ithi.de) or an extended in-house database [22] . Experimental validation of the predicted HLA restriction was obtained by peptide synthesis and functional characterization for a subset of ligands.
Peptide synthesis
Synthetic peptides for the validation of mass spectrometric identifications as well as for functional experiments were synthesized using the automated peptide synthesizer EPS221 (Abimed, Langenfeld, Germany) and the 9-fluorenylmethyloxycarbonyl/tert-butyl (Fmoc/tBu) strategy [28] .
CD8+ T cell priming using aAPC
Priming of CD8+ T cells was performed using artificial antigen-presenting cells (aAPC) according to a standard protocol [35] . PBMC were isolated from fresh buffy coats of healthy volunteers using standard density gradient centrifugation. CD8+ T cells were MACS-enriched by positive selection (Miltenyi Biotec, Bergisch Gladbach, Germany).
In vitro stimulations were initiated in 24-well plates with 5 × 10 6 responder cells plus 10 6 beads per well in 1.5 ml of T cell medium consisting of RPMI 1640 containing 25 mM HEPES (Life Technologies/Invitrogen) supplemented with 10% heat-inactivated human AB serum (CC Pro, Neustadt/ Weinstraße, Germany), 2 mM l-glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, and 20 μg/ml gentamicin (all BioWhittaker/Cambrex, Verviers, Belgium). Five nanograms per milliliter human IL-12 p70 (R&D Systems) was added with aAPC. After 4 days of co-incubation at 37 °C, fresh medium and 20 U/ml human IL-2 (R&D Systems) were added, and cells were incubated for 3 days. This stimulation cycle was repeated twice and tetramer staining was performed on day 21.
Intracellular cytokine and tetramer staining
The frequency and functionality of peptide-specific CD8+ T cells was analyzed by intracellular IFN-γ and TNF-α staining as described previously [21, 39] . PBMC were pulsed with 10 μg/ml of individual peptide and incubated in the presence of 10 μg/ml Brefeldin A (Sigma Aldrich) and 10 μg/ml GolgiStop (BD Biosciences) for 6-8 h. Cells were labeled using Cytofix/Cytoperm (BD Biosciences), CD8-PECy7 (Beckman Coulter, Fullerton, CA, USA), CD4-APC (BD Biosciences), TNFα-PE (Beckman Coulter), and IFNγ-FITC (BD Biosciences). Samples were analyzed on a FACS Canto II (BD, Franklin Lakes, NJ, USA). The frequency of peptide-specific CD8+ T cells was determined by staining with anti-CD8 and HLA:peptide-tetramer-PE [25] . Cultures were considered positive when > 1% of tetramer-positive cells among CD8 + cells were detected.
Cytotoxicity assay
Tetramer-positive cells were enriched by FACS cell sorting (BD FACSAria III, BD Biosciences) and subsequent expansion using irradiated PBMC as feeder cells and 3000 U/ml IL-2 (PeproTech, London, UK) and 30 ng/ml OKT3 (eBioscience, Thermo Fisher). Medium supplemented with IL-2 and OKT3 was changed twice a week. Tetramer-negative cells were expanded in parallel as controls. T cell-mediated GSC lysis was determined using a flow cytometry-based cytotoxicity assay. A single cell suspension of target cells was stained with PKH-26 (Sigma-Aldrich, St. Louis, MO, USA) for 3 min and then co-incubated with T effector cells at different effector to target (E:T) ratios as indicated for 20 h. Subsequently, live/dead staining was performed with Zombie NIR Fixable Viability Kit (BioLegend, San Diego, CA, USA) followed by assessment of target cell lysis by flow cytometry. Specific cell lysis was expressed as percentage of dead cells within the PKH-26-positive target cells, corrected for spontaneous background lysis.
Software, statistical analysis and online tools
Flow cytometric data analysis was performed using FlowJo 7.2 (Tree Star Inc., Ashland, OR, USA). In-house R scripts (https ://www.r-proje ct.org) were used for the calculation of TAA false discovery rates and unsupervised hierarchical clustering of HLA ligand source proteins. Overlap analyses were done using VENNY (Oliveros, J.C. (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) Venny. An interactive tool for comparing lists with Venn's diagrams (http://bioin fogp.cnb.csic.es/tools /venny /index .html) as well as the online tool BioVenn [13] . Functional 
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Annotation charts were created using DAVID (https ://david -d.ncifc rf.gov) [11, 12] . The network analysis of GSC-and patient-specific source proteins was performed using GeneMania (http://www.genem ania.org; default settings) [36] . Bar charts were created using Microsoft Excel 2015 (Redmond, WA, USA), box plots and line graphs were done using Prism 5 (GraphPad Software, San Diego, CA). Kaplan-Meier analysis of survival probability and gene expression analysis for the Glioma-French-284-MAS5.0-u133p2 dataset (n = 284, glioblastoma n = 156) in the database of The Cancer Genome Atlas (TCGA) (http://cance rgeno me.nih.gov) was done using glioblastoma database entries only (n = 156) and using the R2 microarray analysis and visualization platform (http://r2.amc.nl) using a cut off for high expression (top 25%) versus the rest.
Survival was analyzed separately for glioblastoma patients regardless of IDH1 mutation status (n = 156) and for patients with known IDH1 mutation status harboring no IDH1 mutation (IDH1 wt, n = 92).
Results
Mapping the antigenic landscape of naturally presented HLA class I and II ligands on primary glioblastoma and GSC
As a prerequisite for HLA ligandome profiling we analyzed HLA class I and class II expression on GSC (Fig. 1a, b ) and patient samples (Fig. 1c) , showing robust membrane staining for both GSC and patient samples. The workflow of our antigen discovery approach is summarized in Fig. 2a, b . Three different GSC lines (GS-2, GS-5, GS-9) were cultureexpanded and cell pellets (1 ml each) as well as 9 freshly resected glioblastoma samples were snap-frozen. Tumor samples and three experimental replicates per GSC line were used for the isolation of HLA ligands with subsequent analysis by LC-MS/MS in 5 technical replicates. HLA ligandome mapping was done in comparison with an extensive HLA peptidome database. For HLA class I, this database comprised 160 different human normal tissues including central nervous system samples (n = 13) with a total of 46,429 peptides derived from 12,245 source proteins. A list of normal tissues included in this database is provided in Supplementary Table 1 (Online Resource 2). Comparative profiling of HLA ligand source proteins from tumor samples and benign tissue samples was performed separately for HLA class I and II based on the frequency of HLA-restricted representation (Fig. 2c) . The overlap between GSC, patient samples and normal tissues is depicted in Fig. 2d -g for both, source protein and HLA ligand level. HLA class I peptidome analysis of the GSC lines and patient samples yielded a total of 9770 peptide identifications, representing 5703 source proteins. Mapping of the HLA class II ligandome identified 2942 different peptides derived from 1121 distinct source proteins. Basic patient characteristics including HLA typing and peptide yields are provided in Table 1 . The 3 cell lines and 9 patient samples included a total of 23 different HLA-A and -B allotypes; 99.3% of individuals of the Caucasian population have at least one HLA-A or -B allotype that is represented by this tumor dataset (calculated by the IEDB population coverage tool www.iedb. org). The most frequent allotypes were HLA-A*02 (n = 7), -A*03 (n = 6), -B*44 (n = 5), and -B*18 (n = 3). The HLA allotype-dependent population coverage is depicted in Supplementary Fig. 1 (Online Resource 3) . Peptide yields per sample and the length distribution of peptides are shown in Fig. 3a, b. A list of all peptides and corresponding source proteins from tumor samples and normal tissue is provided in Supplementary Table 2 (Online Resource 4).
Gene ontology and network analysis shows enrichment for stem celland development-associated functions of GSC-associated glioblastoma antigens GSC lines is depicted in Fig. 3c . As expected, the overlap was much smaller on the HLA peptidome level compared to the source protein level, mainly due to expression of different HLA allotypes between cell lines. Regarding primary patient samples, a total of 6459 peptides representing 4198 source proteins were identified. Unsupervised hierarchical clustering of HLA ligand source proteins represented on GSC, patient samples or normal brain specimens delineated a distinct cluster for normal brain specimens, which was well separated from the mixed cluster of primary glioblastoma and GSC samples (Fig. 3d) . Notably, normal brain specimens showed a considerable degree of inter-sample homogeneity with a broad set of common antigens represented in their HLA peptidomes. In contrast, primary glioblastoma 
and GSC lines showed high levels of inter-patient/tumor heterogeneity with large blocks of unique antigens represented in their HLA peptidomes indicative of unique tumor biology and/or disruptive effects of malignant transformation on HLA-restricted antigen presentation. Nevertheless, sets of tumor-associated common antigens were identified leading to the distinct clustering of patient tumors and GSC samples. The similarity of individual GSC and patient samples based on the calculation of the Jaccard coefficient is depicted in Supplementary Fig. 2 (Online Resource 9) . The underlying raw data of the clustering is provided in Supplementary Table 7 (Online Resource 10).
Fig. 2
Experimental workflow and overview of HLA ligandome mapping results. a Snap-frozen GSC pellets or snap-frozen glioblastoma patient samples were lysed and HLA molecules were single-step immunopurified using the pan-HLA class I-specific mAb W6/32 covalently linked to CNBr-activated Sepharose. For HLA class II, we used equal amounts of the HLA-DR-specific antibody L243 as well as the pan-HLA class II-specific antibody Tü39. Eluted HLA-peptide ligands were purified by ultrafiltration, desalted and subjected to analysis by LC-MS/MS. b Candidate peptides for immunotherapy were defined by tumor exclusivity, shared presentation on both GSC and patient samples and a sufficient frequency on tumor samples in order to pass false discovery rate criteria for antigens. Peptides mapping into multiple proteins that do not fulfill these criteria were excluded. Candidates fulfilling the criteria mentioned above underwent functional immunogenicity testing. 
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Comparative profiling of HLA class I peptidomes of primary samples and GSC versus normal tissues identifies a subset of GSC-associated glioblastoma antigens
When compared to normal tissues, 224 source proteins were exclusively represented in the HLA peptidome of GSC, 44 proteins were commonly represented on both GSC and solid glioblastoma, and 219 source proteins were specific for primary bulk glioblastoma (Fig. 2e) . The FDR of antigen discovery at different thresholds of tumor-exclusive frequency were estimated based on dataset randomization and are shown for HLA class I in Fig. 4a . Aiming for an antigendiscovery-specific FDR of < 5%, antigens were required to be exclusively presented on at least 3 of 12 (25%) malignant samples leading to an estimated FDR of 3.15% for the identified tumor antigens. Using the criteria of (1) tumorexclusive representation on the HLA peptidome level; (2) common representation on both GSC and primary patient samples, and (3) a frequency of at least 3/12 malignant samples to yield < 5% false-positive antigen discovery, we identified 14 HLA class I antigens represented by 28 HLA ligands [Supplementary Table 8 (Online Resource 11)]. Peptides mapping into multiple proteins that do not fulfill these criteria were excluded. Based on microarray data from TCGA, these candidates are expressed in both glioblastoma samples (Fig. 4c) and normal brain tissue [ Supplementary  Fig. 3 (Online Resource 12) ]. However, differential gene expression was deliberately not a criterion of this antigen discovery approach. As a rough estimate for the relative abundance of candidate peptides within each sample, we plotted the precursor intensity distributions and highlighted candidate peptides in red for GSC (Fig. 4d-f ) and for primary patient specimens [ Supplementary Fig. 4 A minority of HLA class I ligands derived from cancer testis antigens is tumor-exclusive and most of the tumor-exclusive CTA-derived ligands are presented on GSC Cancer testis genes code for a group of immunogenic proteins (CTA, cancer testis antigens) expressed in theory almost exclusively in germ cells located in immunoprivileged sites, but notably also in various human cancer types. This expression pattern led to CTA being considered prime targets for antigen-specific immunotherapy and CTA are targets of ongoing clinical trials in glioblastoma (e.g., NCT02546102 or NCT02208362; http://www.clini caltr ials. gov). Overlap analysis of established CTA (as comprised in CTDatabase; http://www.cta.lncc.br/) and tumor-exclusive source proteins from GSC and patient samples revealed the presentation of 6 CTA represented by 6 corresponding peptides, shown in Fig. 5a , b. The majority of proteins listed in the CTDatabase (133/206; 65%) was neither represented in the HLA ligandome of normal tissues nor on tumor samples. A total of 23/206 (11%) proteins were represented in the HLA ligandome overlap between malignant and benign tissue, 44/206 (21%) were exclusively represented on normal tissues and only a minority of CTA was tumor-exclusive (6/206; 3%). Interestingly, 4/6 (67%) CTA were only identified on GSC although GSC made up only 3/12 (25%) of the samples, indicating aberrant expression or HLA-restricted presentation of these targets selectively on glioblastoma stem cells. Regarding survival analysis, no effects were seen for high expression of the CTA except for an unfavorable prognosis of high interleukin-13 receptor subunit alpha-2 (IL13RA2) expression, which was not the case in the subgroup of IDH1 wild-type tumors [ Supplementary Fig. 5 (Online Resource 14) ].
Mapping the HLA class II ligandome of glioblastoma and GSC extends the options for synergistic immunotherapy
Although the numbers of peptide identifications were lower than on HLA class I, class II peptidome analysis resulted in the identification of 1321 peptides representing 623 source proteins from GSC as well as in 1877 peptides representing 814 source proteins derived from patient samples. Comparative HLA peptidome analysis revealed 137 source proteins and 1260 corresponding peptides to be identified exclusively on malignant samples and 6 source proteins (represented by 26 peptides) to be shared between GSC and patient samples (Fig. 2f, g ). For HLA class II antigen discovery, the FDR threshold was set to a frequency of presentation on at least 3/12 malignant samples resulting in an estimated FDR of 3.33% (Fig. 4b) . Three out of 6 tumor-exclusive proteins shared between GSC and patient samples (SER-PINE1, FABP7, PTGFRN) represented by 13 HLA-bound peptides passed this threshold [Supplementary Table 8 (Online Resource 11)]. Comparing HLA class I and class II peptidomes, we identified 765 dually represented source proteins, 12 of which were tumor-exclusive (Fig. 3e) . We found 263 HLA class I peptide sequences that were embedded within longer HLA class II peptides. Notably, of these, 59 overlapped with HLA class I tumor-exclusive peptide sequences pointing towards an attractive option for synergistic immunotherapy. No differences in survival was seen for the three HLA class II candidate antigens [ Supplementary  Fig. 5 (Online Resource 14) ].
Functional characterization of GSC-associated HLA class I peptides reveals specific immune recognition, degranulation and antigen-specific cytotoxicity of T cells
The top 3 (based on frequency) shared glioblastoma/GSC peptides (all A*02-restricted) ALFPERITV (ATAT1), RLAPFVYLL (HEPACAM), and SILDIVTKV (RFTN2) as well as 2 CTA-derived peptides LLDTNYNLFY (IL13Rα2; A*01-restricted) and FVYGEPREL (MAGEC2; A*02-restricted) were synthesized and subjected to immunological characterization. Peptide-specific immunogenicity was verified by priming of naïve T cells from healthy donors followed by HLA multimer staining (Fig. 6a) . In addition, for ATAT1 and RFTN2 T cells were functionally characterized after priming by intracellular cytokine staining (ICS) detecting the induction of the master pro-inflammatory cytokines interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα) and the degranulation marker CD107a (Fig. 6b) . Supplementary Table 9 (Online Resource 15) summarizes the T cell priming results. Antigen-specific cytotoxicity of T cells after sorting of tetramer-positive CD8+ T 1 3 
Discussion
By (1) mapping the natural immunopeptidome of the glioblastoma stem cell compartment, (2) a first description of the HLA class II ligandome in glioblastoma (3) the definition of a novel subset of GSC-associated antigens in glioblastoma, which were defined based on direct evidence on the immunologically pivotal level of HLA-restricted antigen presentation, rather than based on gene expression and/or in silico predictions, our study may help guiding the informed design of immunotherapeutic interventions targeting the glioblastoma stem cell compartment. Notably, the potential of targeting HLA class II-restricted antigens was recently underscored by clinical data on the crucial role of HLA class II and CD4+ T cells in immunological tumor rejection [17, 26, 30] . Furthermore, detailed knowledge on natural HLA class II antigen presentation patterns will allow for tailoring multi-epitope peptide vaccines containing both HLA class I-and HLA class II-restricted targets, which may induce and boost synergistic CD8+ and CD4+ anti-tumor responses.
A major focus of this study was the comparative analysis of the ligandome of GSC and patient samples with the aim of identifying GSC-associated targets also present on primary patient tumors. Bearing in mind that GSC are culture-expanded ex vivo and therefore subject to potential cell culture artifact, we performed a comparative side-byside analysis of GSC and patient samples. Freshly resected glioblastoma patient samples represent the natural state of the HLA peptidome of glioblastoma as present in vivo. However, freshly resected patient samples are contaminated by non-tumorous cells (i.e., endothelium, microglia, infiltrating leukocytes and leukocytes from blood contamination). In contrast, GSC are composed of tumor cells only, thus tumorexclusive patient sample-derived ligands that can also be found on GSC are unlikely to be derived from non-tumorous cells. Vice versa, GSC-derived HLA ligands that can also be found in freshly resected patient samples are unlikely to be an artifact of cell culture. In addition, hierarchical clustering analysis of HLA class I peptidomes clearly delineated normal brain samples as a distinct cluster, whereas GSC were determined to be more similar to patient samples. Another advantage of focusing on the overlap between GSC and primary patient samples is the potential similarity between GSC and adult stem cells. As GSC and normal neuroglial stem cells might share common properties [38] , a high acuity of separation between these two is needed in order to prevent collateral damage to the physiological stem cell pool. Together, this strongly suggests antigens identified by our strategy represent naturally presented and highly specific targets for the immunotherapy of the glioblastoma stem cell compartment.
Recently, an antigen discovery approach for GSC-associated T cell targets was presented by Rapp and colleagues, which is based on proteomics and subsequent immunogenicity testing [23] . Peptides used for immunogenicity assays were based on in silico predictions. Albeit the abundance and turnover of source proteins has been shown to globally correlate with HLA class I-restricted peptide presentation [3] , there is still a high degree of variability in sampling for HLA-restricted presentation for individual proteins, which warrants the direct analysis of HLA peptidomes for antigen discovery. Therefore, we strictly relied on HLA peptidome level analyses to identify targets by comparative HLA ligandome profiling of GSC and patient samples in relation to a comprehensive database of various human normal tissues including human brain. Both approaches complement each other and add important targets for immunotherapy of glioblastoma including the GSC compartment.
Regarding HLA ligands derived from CTA it is worth noting that 4/6 (67%) of CTA were solely identified on GSC, although GSC only contribute 3/12 (25%) of the samples. We hypothesize that this over-representation of CTA on GSC might be due to a shift towards germ-line gene expression patterns and an undifferentiated phenotype of GSC, which is consistent with the findings of our network analysis. This is in line with previous findings of enhanced CTA expression in GSC [42] . Interestingly, the 3686 HLA-A*02-restricted peptides identified on freshly resected glioblastoma in a previous study by Dutoit et al. [7] did not include previously reported HLA-A*02-restricted glioblastoma peptides from EGFRvIII, Eph-2A, gp100, HER2, IL-13Rα2, MAGEA1, TRP-2, SOX-2, -3, -11 and WT1 [6] . Dutoit et al. identified peptides derived from EGFR and Eph-A2 other than the previously published ones. We found peptides derived from MAGEA1, SOX-2, SOX-11 und IL-13Rα2, which all were detected on GSC and never on patient samples. In addition, all peptides derived from these source proteins were restricted to HLA allotypes other than HLA-A*02. This could further highlight the importance of analyzing GSC as a source of suitable antigens and also underscores the importance of mapping non-HLA-A*02 peptidomes for antigen discovery. Of note, the HLA-A*01-restricted peptide LLDTNYNLFY is derived from the source protein IL13Rα2. Recently, a report of glioblastoma tumor regression after intracranial infusion of IL13Rα2-targeted chimeric antigen receptor (CAR) T cells was published [5] , which supports the utility of IL13Rα2 as a potential target for immunotherapy.
The increasing availability of next generation sequencing was accompanied by a shifting focus towards mutationderived neoepitopes. These neoantigens are, in theory, tumor-specific and immunogenic and recent studies showed promising clinical results in malignancies other than glioblastoma [24, 30, 32] . Our approach is not designed or able to detect neoantigens as all mass spectrometry data acquired in this study was uniformly processed against a reference proteome. However, this enables us to sensitively detect nonmutated antigens derived from "self", which are well established in tumor immunology [31, 34] and recently have been shown to be targets of pathophysiologically relevant anticancer immune responses in leukemia patients [15] . Compared to other malignancies, the number of somatic mutations in glioblastoma is rather low [1] . Even in tumors with a high mutational burden, peptides derived from mutated sequences are exceedingly rare [41] . In general, the number of mutated tumor antigens that elicit frequent and effective anti-tumor immune responses appears to be quite small even in the setting of checkpoint inhibition [2, 18] . A reason for the low prevalence of neoantigens even in tumors with high mutational burden might be a clonal selection of neoantigen loss variants by immunoediting [33] .
A limitation of this study is the low number of normal brain tissues and the variation of HLA allotypes on the normal tissue side. In theory, target candidates may loose their tumor exclusivity by future expansion of the normal issue database. However, the potential utility of candidate targets from our comparative approach is strengthened by the evidence of antigen-specific T cell populations in functional assays. Overall, the HLA-centric antigen discovery approach implemented in our study highlights a strategy to broaden the repertoire of targetable antigens by adding a novel class of GSC-associated antigens, which-upon further target validation-may be utilized in both patient-individualized and off-the-shelf approaches. 
